Q-omics provides the consensus-scored KHDRBS2-OT1 profile across patient tissues and cancer cell-line models. KHDRBS2-OT1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, KHDRBS2-OT1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, KHDRBS2-OT1 RNA expression shows 20,495 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, THCA, and GBM as cancer lineages where KHDRBS2-OT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KHDRBS2-OT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KHDRBS2-OT1 survival associations across molecular data types. KHDRBS2-OT1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KHDRBS2-OT1 RNA expression–survival associations across cancer types. High KHDRBS2-OT1 expression shows unfavorable associations in COAD and KICH, but favorable associations in PAAD, LUAD, ESCA and LGG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for KHDRBS2-OT1 RNA expression.
This table summarizes KHDRBS2-OT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KHDRBS2-OT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KHDRBS2-OT1 shows lower tumor expression in THCA, LUAD, LUSC, BLCA, HNSC and COAD. The THCA box plot shows higher KHDRBS2-OT1 RNA expression in normal versus tumor tissue (log2 FC = −1.910, t-test p < 0.001).
This table shows molecular features associated with KHDRBS2-OT1 in patient tissues and cancer cell lines. In patient samples, KHDRBS2-OT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
